Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이순남 | * |
dc.contributor.author | 남은미 | * |
dc.date.accessioned | 2018-06-02T08:14:53Z | - |
dc.date.available | 2018-06-02T08:14:53Z | - |
dc.date.issued | 2002 | * |
dc.identifier.issn | 1341-9625 | * |
dc.identifier.other | OAK-17235 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/244305 | - |
dc.description.abstract | Background. Docetaxel is highly active in the second-line treatment of patients with metastatic or unresectable locally advanced nonsmall-cell lung cancer (NSCLC). As there is a need for first-line chemotherapy that is more effective than standard platinum-based chemotherapy, this study was undertaken to evaluate the efficacy and tolerability of a docetaxel/cisplatin combination as first-line chemotherapy in advanced NSCLC. Methods. Newly diagnosed, chemotherapy-naive patients with histologically confirmed NSCLC (measurable stage IIIB/IV NSCLC; Karnofsky performance status, 70-100; adequate bone marrow, renal, hepatic, and cardiac function) were eligible for the study. Docetaxel 75mg/m2 was administered IV over 1 h, followed immediately by cisplatin 75mg/m2, given IV over 30min, with cycles repeated every 3 weeks, for up to six or nine cycles. Results. Thirty-nine patients were enrolled and treated. Their median age was 59 years (range, 32-71 years) and median performance status, 90 (range, 70-100). Histologically, 23 patients (59%) had adenocarcinoma, 12 (30.8%) had squamous cell carcinoma, and 16 patients (41%) had stage IV disease. Thirty-seven patients were eligible for inclusion. In the 39 patients evaluable for safety, significant grade 3/4 toxicities included neutropenia (82%), nausea (10.3%), fatigue (10.3%), and diarrhea (7.7%). Of the 33 patients evaluable for response, 16 patients (48.5%) achieved a partial response and 7 showed progressive disease. Median overall survival time in all eligible patients was 10.5 months. Conclusion. Docetaxel/cisplatin produced promising response rates that compare favorably with those of current standard platinum combinations, with manageable toxicity. Further investigations of this first-line combination in NSCLC are warranted. | * |
dc.language | English | * |
dc.title | Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 7 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 114 | * |
dc.relation.lastpage | 119 | * |
dc.relation.journaltitle | International Journal of Clinical Oncology | * |
dc.identifier.scopusid | 2-s2.0-0036001439 | * |
dc.author.google | Kim Y.H. | * |
dc.author.google | Kim J.S. | * |
dc.author.google | Choi Y.H. | * |
dc.author.google | In K.H. | * |
dc.author.google | Park H.S. | * |
dc.author.google | Hong D.S. | * |
dc.author.google | Jeong T.J. | * |
dc.author.google | Lee Y.Y. | * |
dc.author.google | Nam E. | * |
dc.author.google | Lee S.N. | * |
dc.author.google | Lee K.S. | * |
dc.author.google | Kim H.K. | * |
dc.contributor.scopusid | 이순남(8422735900;56949372000) | * |
dc.contributor.scopusid | 남은미(7005824288;57226666155) | * |
dc.date.modifydate | 20240301081003 | * |